Leap Therapeutics, Inc. (LPTX): Price and Financial Metrics


Leap Therapeutics, Inc. (LPTX)

Today's Latest Price: $1.80 USD

0.01 (-0.55%)

Updated Jul 16 12:08pm

Add LPTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

LPTX Daily Price Range
LPTX 52-Week Price Range

LPTX Stock Price Chart Technical Analysis Charts


LPTX Price/Volume Stats

Current price $1.80 52-week high $3.18
Prev. close $1.81 52-week low $0.57
Day low $1.78 Volume 212,606
Day high $1.85 Avg. volume 705,789
50-day MA $2.23 Dividend yield N/A
200-day MA $1.71 Market Cap 100.61M

Leap Therapeutics, Inc. (LPTX) Company Bio


Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in acquiring and developing therapeutics in cancer biology. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


LPTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

LPTX Latest Social Stream


Loading social stream, please wait...

View Full LPTX Social Stream

Latest LPTX News From Around the Web

Below are the latest news stories about Leap Therapeutics Inc that investors may wish to consider to help them evaluate LPTX as an investment opportunity.

Benzinga's Top Upgrades, Downgrades For June 29, 2020

Upgrades * SunTrust Robinson Humphrey changed the rating for CoreLogic Inc (NYSE: CLGX) from Hold to Buy. In the first quarter, CoreLogic showed an EPS of $0.76, compared to $0.45 from the year-ago quarter. The stock has a 52-week-high of $68.40 and a 52-week-low of $24.69. CoreLogic's stock last closed at $67.95 per share. * For Big Lots Inc (NYSE: BIG), Loop Capital upgraded the stock from Hold to Buy. For the first quarter, Big Lots had an EPS of $1.26, compared to year-ago quarter EPS of $0.92. The stock has a 52-week-high of $44.90 and a 52-week-low of $10.12. Big Lots's stock last closed at $43.02 per share. * For Southwest Airlines Co (NYSE: LUV), Goldman Sachs upgraded the stock from Sell to Buy. For the first quarter, Southwest Airlines had an EPS of ($0.15), compar...

Yahoo | June 29, 2020

Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters' option to purchase additional shares from Leap's previously announced public offering. After giving effect to the full exercise of the option, the aggregate gross proceeds to Leap from this offering were approximately $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap.

Yahoo | June 25, 2020

Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., June 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of common stock and pre-funded warrants to…

PR Newswire | June 22, 2020

Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $1.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Leap from this offering are expected to be approximately $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Leap. All shares of common stock and pre-funded warrants to be sold in t...

Yahoo | June 18, 2020

Leap Therapeutics initiates stock offering

Leap Therapeutics (LPTX) launches a public offering of common stock. Price, volume and terms have yet to be announced.Shares down 13% after hours....

Seeking Alpha | June 17, 2020

Read More 'LPTX' Stories Here

LPTX Price Returns

1-mo -29.96%
3-mo 3.45%
6-mo 1.12%
1-year -9.55%
3-year -75.27%
5-year N/A
YTD 60.71%
2019 -44.00%
2018 -67.95%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.945 seconds.